Received Aug 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
swollen shut eyes; itchy eyes; This non-serious case was reported by a consumer and described the occurrence of eye swelling in a 54-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included Varicella zoster vaccine rgE (CHO) (Shingrix). On 24-JUL-2025, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced eye swelling (Verbatim: swollen shut eyes) and eye pruritus (Verbatim: itchy eyes). Rechallenge with Shingrix was positive. The outcome of the eye swelling and eye pruritus were not reported. It was unknown if the reporter considered the eye swelling and eye pruritus to be related to Shingrix. It was unknown if the company considered the eye swelling and eye pruritus to be related to Shingrix. Linked case(s) involving the same patient: US2025096594 Additional Information: GSK receipt date: 28-JUL-2025 The patient had itchy and swollen shut eyes after the 2nd shot of Shingrix.; Sender's Comments: US-GSK-US2025096594:Same patient 1st dose
SHINGRIX